NCT01727986已完成3 期
Extension, Open-label, Interventional, Long-term Study to Evaluate the Safety of Tocilizumab Treatment in Patients From Brazil With Polyarticular-course Juvenile Idiopathic Arthritis Who Completed the Global Multinational Trial (WA19977)
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 11
- 主要终点
- Long-term safety: Incidence of adverse events
研究概览
简要总结
This long-term, open-label extension study will evaluate the safety of RoActemra/Actemra (tocilizumab) in patients with polyarticular-course juvenile idiopathic arthritis who completed the WA19977 core study. Patients aged 9-18 years with at least JIA ACR30 clinical response to RoActemra/Actemra in the core study will be eligible to receive RoActemra/Actemra 8 mg/kg intravenously every 4 weeks. Anticipated time on study treatment is 104 weeks.
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 9 Years 至 18 Years（Child, Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients 9 to 18 years of age who completed visit 33 (week 104) of WA19977 study with at least JIA ACR30 clinical response to RoActemra/Actemra relative to baseline in WA19977, with no AEs, SAEs or conditions that lead to unacceptable risk of continued treatment
- •Females of child-bearing potential and males with female partners of child-bearing potential must agree to use effective contraception as defined by protocol
排除标准
- •Patients with, according to investigator judgment, not satisfactory benefit from RoActemra/Actemra therapy within WA19977
- •Treatment with any investigational agent since the last administration of study drug in the core study WA19977 or current participation in another clinical trial except WA19977
- •Patient developed any other autoimmune rheumatic disease or overlap syndrome other than the permitted polyarticular-course JIA subsets: rheumatoid factor positive or negative JIA or extended oligoarticular JIA
- •Patient is pregnant , lactating, or intending to become pregnant during the study and up to 12 weeks after the last administration of study drug
- •Any significant concomitant disease or medical or surgical condition
- •History of significant allergic or infusion reactions to prior biologic therapy
- •Currently active primary or secondary immunodeficiency
- •Current abuse of alcohol, drugs or chemical abuse
- •Known and currently active acute, subacute, chronic infections or history of recurrent infection; patients suffering from ongoing active infections with Epstein Barr virus, herpes zoster or recurrent history of urinary tract infection can be included after the (acute) infection has been excluded or subsided
- •Positive for latent tuberculosis (TB)
- •Currently active asthma for which the patient has required the use of oral or parenteral corticosteroids for >/= 2 weeks within 6 months prior to entering the study
- •Inadequate hepatic, renal or bone marrow function
研究组 & 干预措施
RoActemra/Actemra
Experimental
干预措施: tocilizumab [RoActemra/Actemra] (Drug)
结局指标
主要结局
Long-term safety: Incidence of adverse events
时间窗: approximately 3 years
次要结局
- Response rates according to the American College of Rheumatology criteria for juvenile idiopathic arthritis (JIA ACR)(approximately 3 years)
- Proportion of patients achieving inactive disease/clinical remission(approximately 3 years)
研究者
相似试验
已完成
3 期
A Long-Term Extension Study of RoActemra/Actemra (Tocilizumab) in Patients With Juvenile Idiopathic Arthritis Who Completed WA19977 Core StudyJuvenile Idiopathic ArthritisNCT01667471Hoffmann-La Roche6
已完成
3 期
A Long-Term Extension Study of RoActemra/Actemra (Tocilizumab) in Patients With Juvenile Idiopathic Arthritis From France Who Completed WA19977 Core StudyJuvenile Idiopathic ArthritisNCT01673919Hoffmann-La Roche7
已完成
3 期
A Study of RoActemra/Actemra (Tocilizumab) Plus DMARDs in Patients With Rheumatoid ArthritisRheumatoid ArthritisNCT01214733Hoffmann-La Roche30
已完成
3 期
A Long-Term Safety Extension Study of WA19926 in Participants With Rheumatoid ArthritisRheumatoid ArthritisNCT01649804Hoffmann-La Roche12
已完成
不适用
An Observational Study on Long-Term Efficacy and Safety of RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Rheumatoid Arthritis (FAct)Rheumatoid ArthritisNCT01483326Hoffmann-La Roche215